MX2022001741A - Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina. - Google Patents

Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina.

Info

Publication number
MX2022001741A
MX2022001741A MX2022001741A MX2022001741A MX2022001741A MX 2022001741 A MX2022001741 A MX 2022001741A MX 2022001741 A MX2022001741 A MX 2022001741A MX 2022001741 A MX2022001741 A MX 2022001741A MX 2022001741 A MX2022001741 A MX 2022001741A
Authority
MX
Mexico
Prior art keywords
salt
compound
crystalline forms
forms
kinase inhibitor
Prior art date
Application number
MX2022001741A
Other languages
English (en)
Spanish (es)
Inventor
Clare Medendorp
Debra Mazaik
Gordon Wilkie
Joshua D Waetzig
Brian Heinrich
Lauren Maceachern
Dominik Siegel
Harald Ohmer
Steven C Johnston
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of MX2022001741A publication Critical patent/MX2022001741A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2022001741A 2019-08-13 2020-08-12 Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina. MX2022001741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885977P 2019-08-13 2019-08-13
PCT/US2020/045847 WO2021030386A1 (en) 2019-08-13 2020-08-12 Salt and crystal forms of an activin receptor-like kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2022001741A true MX2022001741A (es) 2022-03-11

Family

ID=72193669

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022001741A MX2022001741A (es) 2019-08-13 2020-08-12 Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina.
MX2024014312A MX2024014312A (es) 2019-08-13 2022-02-09 Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024014312A MX2024014312A (es) 2019-08-13 2022-02-09 Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina

Country Status (15)

Country Link
US (1) US20220281879A1 (cg-RX-API-DMAC10.html)
EP (1) EP4013757A1 (cg-RX-API-DMAC10.html)
JP (2) JP7775186B2 (cg-RX-API-DMAC10.html)
KR (1) KR102967623B1 (cg-RX-API-DMAC10.html)
CN (2) CN114222745B (cg-RX-API-DMAC10.html)
AU (1) AU2020328534B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022002597A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146701A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022001450A2 (cg-RX-API-DMAC10.html)
IL (1) IL290482A (cg-RX-API-DMAC10.html)
JO (1) JOP20220014A1 (cg-RX-API-DMAC10.html)
MX (2) MX2022001741A (cg-RX-API-DMAC10.html)
TW (1) TWI870440B (cg-RX-API-DMAC10.html)
UA (1) UA130650C2 (cg-RX-API-DMAC10.html)
WO (1) WO2021030386A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2026161341A1 (en) * 2025-01-21 2026-07-30 Blueprint Medicines Corporation Drug product formulations of fidrisertib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol

Also Published As

Publication number Publication date
TWI870440B (zh) 2025-01-21
KR20220052955A (ko) 2022-04-28
AU2020328534A1 (en) 2022-03-17
JP2022544272A (ja) 2022-10-17
JP2025148406A (ja) 2025-10-07
JOP20220014A1 (ar) 2023-01-30
US20220281879A1 (en) 2022-09-08
WO2021030386A1 (en) 2021-02-18
EP4013757A1 (en) 2022-06-22
CN114222745A (zh) 2022-03-22
AU2020328534B2 (en) 2026-04-30
UA130650C2 (uk) 2026-04-08
BR112022002597A2 (pt) 2022-07-05
CN119638704A (zh) 2025-03-18
JP7775186B2 (ja) 2025-11-25
TW202120509A (zh) 2021-06-01
CO2022001450A2 (es) 2022-05-31
CN114222745B (zh) 2025-03-25
MX2024014312A (es) 2024-12-06
KR102967623B1 (ko) 2026-05-21
CA3146701A1 (en) 2021-02-18
IL290482A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
CO2022001450A2 (es) Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina
MX2022009998A (es) Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1- carbonil)fenil)quinolin-8-sulfonamida.
CY1122468T1 (el) Κρυσταλλικη μορφη διθειικου αναστολεα κινασης jak και μια μεθοδος παρασκευης αυτου
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MX376500B (es) Forma cristalina del inhibidor de la btk quinasa y método de preparación de la misma.
PH12020550575A1 (en) Salts of pi3k inhibitor and processes for their preparation
MX384087B (es) Piperidinas como inhibidores de menina.
MX2016009135A (es) Heteroarilos y usos de estos.
MX2020004148A (es) Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf).
EP4248988A3 (en) Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
SA520411638B1 (ar) Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ
MX2019012945A (es) Formas cristalinas de un compuesto inhibidor de jak.
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
WO2018044767A3 (en) Aminopyrimidines as alk inhibitors
AR100818A1 (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
MX387359B (es) Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
CR20160558A (es) Compuesto de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
CL2021000903A1 (es) Nhibidores de ror gamma (solicitud divisional de la solicitud 217-2020
MX2022001608A (es) Sintesis de un inhibidor de calicreina plasmatica a escala de proceso.
PY1976957A (es) Formas cristalinas de un compuesto de quinazolina y sus sales de clorhidrato.-
GEP20227437B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
MX2023004115A (es) Compuestos del inhibidor de la autotaxina.
AR110998A1 (es) Inhibidores de la tirosina cinasa de bruton
SA522431923B1 (ar) عملية لتحضير دواء